Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ioxitalamate→

Ioxitalamate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
28179-44-4
Molecular formula
C12H11I3N2O5
Molecular weight
643.94 g/mol
Drug class
Ionic iodinated X-ray contrast mediumhigh-osmolar triiodinated benzoate
Mechanism of action
Ioxitalamate is a water-soluble ionic tri-iodinated contrast agent. Its iodine atoms attenuate X-rays, increasing radiographic contrast in vascular and other extracellular spaces. Meglumine and sodium salts are formulation counterions; the labelled contrast formulation determines route and indication.
Indications / reported uses
  • Radiographic contrast enhancement for angiography, urography and other X-ray or CT examinations according to the specific salt, formulation and product label.
  • Oral or rectal contrast use in selected gastrointestinal imaging protocols with products specifically labelled for those routes.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13282205/ · https://pubchem.ncbi.nlm.nih.gov/#query=ioxitalamate · https://www.ncbi.nlm.nih.gov/mesh/?term=ioxitalamate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ioxitalamate Environmental Risk Assessment (ERA) (the Ioxitalamate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.